Description
Kesimpta (ofatumumab) is a prescription medication for treating relapsing forms of multiple sclerosis (MS). It is a monoclonal antibody that targets and binds to a specific protein found on the surface of B-cells, a type of immune cell involved in the development of MS.
Kesimpta is available in a prefilled syringe and is administered as a subcutaneous injection.
Fact Table |
Formula |
C6480H10022N1742O2020S44 |
License |
US FDA, EU EMA |
Bioavailability |
70% |
Legal status |
Rx-Only |
Chemical Name |
Ofatumumab |
Elimination half-life |
14 days |
Dosage (Strength) |
- |
Pregnancy |
Consult Doctor |
Brands |
kesimpta |
Protein binding |
Limited information |
PubChem CID |
Not Available |
MedlinePlus |
a621050 |
ChEBI |
Not Available |
ATC code |
L01FA02 |
DrugBank |
DB06650 |
KEGG |
D09314 |
Routes of administration |
Subcutaneous |
Directions
The first dose is administered alongside a healthcare professional. Your healthcare provider will provide you with a schedule for subsequent injections.
Ingredients
The active ingredient in Kesimpta is ofatumumab.
Interactions
Common drug-drug interactions may include:
- Abrocitinib
- Baricitinib
- BCG Products
- Cladribine
- Coccidioides immitis Skin Test
- COVID-19 Vaccines
- Dengue Tetravalent Vaccine
- Denosumab
- Deucravacitinib
- Filgotinib
- Influenza Virus Vaccines
- Leflunomide
- Mumps- Rubella- or Varicella-Containing Live Vaccines
- Nadofaragene Firadenovec
- Natalizumab
- Ocrelizumab
- Pimecrolimus
- Poliovirus Vaccine
- Polymethylmethacrylate
- Rabies Vaccine
- Ruxolitinib
- Sipuleucel-T
- Tacrolimus
- Talimogene Laherparepvec
- Tertomotide
- Tofacitinib
- Typhoid Vaccine
- Upadacitinib
- Vaccines (Inactivated/Non-Replicating)
- Vaccines (Live)
- Yellow Fever Vaccine
Cautions
Do not take Kesimpta if you are allergic to ofatumumab or any other ingredient in the medication.
Before starting Kesimpta, inform your healthcare provider if you have a history of hepatitis B infection, as the medication may reactivate the virus.
It is important to monitor for signs of infection while using Kesimpta, as it may increase the risk of infection.
Side Effects
The most common side effects of Kesimpta may include:
- Anemia
- Back pain
- Bronchitis
- Chills
- Cough
- Decreased serum immunoglobulins
- Diarrhea
- Dyspnea
- Fatigue
- Fever
- Headache
- Hepatitis B
- Herpes zoster infection
- Hyperhidrosis
- Hypertension
- Hypogammaglobulinemia
- Hypotension
- Infection
- Influenza
- Infusion-related reaction
- Injection site reaction
- Insomnia
- Muscle spasm
- Nasopharyngitis
- Neutropenia
- Peripheral edema
- Pneumonia
- Porphyria cutanea tarda
- Progressive multifocal leukoencephalopathy
- Sepsis
- Serious Infection
- Sinusitis
- Skin rash
- Stevens-Johnson syndrome
- Tachycardia
- Tumor lysis syndrome
- Upper respiratory tract infection
- Urinary tract infection
- Urticaria
References
Kesimpta [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2020.
About Dr. Conor Sheehy (Page Author)
Dr. Sheehy (BSc Molecular Biology, PharmD) works a clinical pharmacist specializing in cardiology, oncology, and ambulatory care. He’s a board-certified pharmacotherapy specialist (BCPS), and his experience working one-on-one with patients to fine tune their medication and therapy plans for optimal results makes him a valuable subject matter expert for our pharmacy. Read More....
IMPORTANT NOTE:
The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.
Product Code : 13855